Sustanon 250 — Competitive Intelligence Brief

Sustanon 250 (Sustanon 250) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anabolic steroid. Area: Endocrinology.

phase 3 Anabolic steroid Androgen receptor Endocrinology Small molecule

Target snapshot

Sustanon 250 (Sustanon 250) — Jules Bordet Institute. Sustanon 250 is an oil-based injectable testosterone blend used to treat low testosterone levels in men.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sustanon 250 TARGET	Sustanon 250	Jules Bordet Institute	phase 3	Anabolic steroid	Androgen receptor
Talazoparib with enzalutamide	talazoparib-with-enzalutamide	Pfizer	marketed	PARP inhibitor and androgen receptor inhibitor	PARP enzymes and androgen receptor	Not yet launched
Winlevi	CLASCOTERONE	Sun Pharma	marketed	Androgen Receptor Inhibitor [EPC]	Androgen receptor	2020-01-01
Nubeqa	darolutamide	Bayer	marketed		androgen receptor (AR)	2019-01-01
Erleada	apalutamide	Johnson & Johnson	marketed		Androgen receptor	2018-01-01
APALUTAMIDE	APALUTAMIDE		marketed		Androgen Receptor (AR)	2018-01-01
Aveed	TESTOSTERONE UNDECANOATE	Marius	marketed	Androgen	Androgen receptor	2014-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anabolic steroid class)

1. Jules Bordet Institute · 1 drug in this class